Sponsor:
Anagram Therapeutics, Inc.
Code:
NCT07450547
Conditions
Exocrine Pancreatic Insufficiency (EPI)
Cystic Fibrosis (CF)
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
ANG003 Dose A
ANG003 Dose B
Creon
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-12. This information was provided to ClinicalTrials.gov by Anagram Therapeutics, Inc. on 2026-05-08.